보고서 요약(국문)

바이러스 벡터 제조 시장 개요
바이러스 벡터 제조 시장 규모는 2022년 6억 7,850만 달러였으며, 2023년부터 2030년까지 연평균 성장률(CAGR) 20.30%로 성장할 것으로 예상됩니다. 바이러스 벡터를 생산하기 위해서는 먼저 적절한 세포를 배양한 후, 일반적으로 플라스미드 제형을 사용하여 형질전환시켜야 합니다. 이렇게 생산된 바이러스 벡터는 세포에서 추출하여 유전자 치료 또는 CAR-T 세포 치료와 같은 환자 세포 치료제로 사용하기 위한 제형으로 만들어집니다. 예를 들어, 치료 유전자 전달에 흔히 사용되는 바이러스 유형 중 하나인 아데노바이러스 벡터의 제조에는 부착 세포 배양 조건이 필요합니다. 부착 세포 배양에서 세포는 특정 기질에 지지되며, 가장 일반적인 두 가지 방법은 마이크로캐리어와 다중 트레이 정적 플라스틱 용기를 사용하는 것입니다.

바이러스 벡터 제조 시장 동향 및 추세
전 세계 바이러스 벡터 제조 시장은 기술 발전, 유전자 치료의 도입 증가, 플라스미드 DNA 수요 증가, 그리고 유전자 치료 기술의 발전으로 성장하고 있습니다.
유전자 치료에 대한 수요 증가가 시장 성장을 견인합니다.
질병 부담 증가, 신제품 출시, 그리고 기술 발전은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 인간 게놈에 특정한 변화를 줄 수 있는 능력은 수십, 아니 수백 가지 질병의 근본 원인을 해결할 수 있는 가능성을 제시하지만, 이러한 치료법의 혁신적인 잠재력이 고소득 국가에만 국한될 것이라는 우려도 있습니다. 세계경제포럼(WEF)에 따르면, 2022년 10월 기준으로 매년 30만 명 이상의 아기가 겸상 적혈구 질환을 가지고 태어났습니다. 이 중 약 75%는 사하라 이남 아프리카에서, 약 17%는 아랍-인도 지역에서 발생했습니다. 이러한 막대한 건강 문제를 해결하기 위해서는 개선된 검진과 더 나은 1차 진료가 필요하며, 이는 전 세계 바이러스 벡터 제조 시장의 성장을 견인할 것입니다.

또한 주요 기업들은 사업 확장을 위해 협력 및 신제품 출시와 같은 시장 전략을 활용하고 있습니다. 예를 들어, AGC Biologics는 2022년 5월 콜로라도주 롱몬트에 위치한 상업용 캠퍼스에 바이러스 벡터 현탁액 기술과 유전자 치료제 개발 및 제조 역량을 추가한다고 발표했습니다. 또한, Merck는 2021년 10월 유전자 치료제용 바이러스 벡터 위탁 개발 및 제조 시설을 신설하여 글로벌 위탁 개발 및 제조 조직의 범위를 확대했습니다. 같은 달, LEXEO Therapeutics는 FUJIFILM Diosynth Biotechnologies와 협력하여 LEXEO의 AAV 매개 유전자 치료제 개발 및 제조를 추진했습니다.
더 나아가, Fujifilm Corporation은 2021년 1월 바이러스 벡터 생산 및 관련 연구를 위한 새로운 가공 시설 건설에 4천만 달러를 투자할 계획을 발표했습니다. 또한, 2021년 1월 코브라 바이오로직스(찰스 리버 래버러토리스)는 유럽과 미국 내 제조 시설을 확장했습니다. 여기에는 본사 DNA 제조 시설을 4배로 확장하고 유럽에 새로운 시설을 건설하는 것이 포함됩니다.
바이러스 벡터 제조 과정에서 발생하는 어려움은 시장 성장을 저해할 것입니다.
백신 벡터 제조 절차는 비교적 정형화되어 있지만, 다양한 특성을 가진 여러 바이러스를 사용할 수 있기 때문에 몇 가지 어려움이 발생할 수 있습니다. 대형 바이러스 벡터의 경우, 무균 여과로 인한 수율 손실 때문에 공정 무균성이 필수적입니다. 벡터 응집 및 안정성 문제도 존재합니다.
코로나19가 바이러스 벡터 제조 시장에 미치는 영향
코로나19의 발생은 전 세계 바이러스 벡터 제조 시장에 긍정적인 영향을 미쳤습니다. 사이티바(Cytiva)에 따르면, 코로나19 바이러스 벡터 백신 제조로 인해 이미 공급이 부족한 키메라 항원 수용체(CAR)-T 세포 치료제 회사들은 핵심 시약에 대한 높은 수요로 인해 추가적인 압박을 받고 있습니다. 유전자 치료 및 바이러스 백신용 바이러스 벡터 제조 분야에서, 특히 팬데믹 발생 이후 백신 제조 역량에 대한 수요가 급증했습니다.
CAR-T 및 백신 생산 시장 참여자들은 바이러스 벡터 생산 업체의 역량을 확보하기 위해 경쟁하고 있는데, 이는 아데노바이러스, 렌티바이러스, 아데노연관바이러스 벡터 생산 역량이 대부분 동일하기 때문입니다. 아데노바이러스 벡터는 아스트라제네카와 존슨앤존슨의 코로나19 백신, 러시아의 스푸트니크-V 백신 등에 사용됩니다. 렌티바이러스 벡터는 CAR-T 백신 생산에 자주 사용됩니다. 예를 들어, 2021년 4월에는 존슨앤존슨의 얀센 제약이 베스 이스라엘 디코니스 메디컬 센터와 공동으로 개발한 SARS-CoV-2에 대한 아데노바이러스 벡터 기반 백신인 JNJ-78436735(Ad26.COV2.S)가 유럽 의약품청의 승인을 받았습니다.

바이러스 벡터 제조 시장 세분화 분석
아데노바이러스 벡터 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
아데노바이러스 벡터 부문은 가장 큰 시장 점유율을 차지하고 있습니다. CEVEC Pharmaceuticals 2021에 따르면, 바이러스 벡터는 다양한 의료 분야에서 점점 더 중요해지고 있습니다. 아데노바이러스(Ad) 벡터는 여러 바이러스 벡터 중에서도 오랜 기간 사용되어 왔습니다. 최근 아데노바이러스 벡터 기반 코로나19 백신인 Vaxzevria(옥스퍼드/아스트라제네카)와 Janssen COVID-19 백신(존슨앤존슨)이 승인되면서 더욱 주목받고 있습니다. 또한, 백신 생산에서 아데노바이러스 벡터는 유전자 치료 및 종양 용해 바이러스 분야에서 가장 적합한 전달 도구 중 하나로 사용됩니다.

백신 생산에 있어 아데노바이러스(Ad) 벡터의 장점으로는 우수한 안전성, 필수적인 세포성 및 체액성 면역 반응 유도 능력, 증식 세포와 휴면 세포 모두에 대한 적절한 유전자 전달, 비교적 용이한 벡터 구성, 높은 역가의 신속한 바이러스 생산 가능성, 그리고 안정성 등이 있습니다. 유전자 치료 또는 백신 생산에서 전달체로서 Ad 벡터의 필수적인 안전성 특징은 복제 불능성입니다. 이는 바이러스가 환자의 세포에 필수 유전자를 도입한 후에는 무질서하게 증식할 수 없다는 것을 의미합니다.
이를 위해 Ad 야생형 게놈은 다양한 방식으로 변형되었습니다. 유전자 치료 및 백신 생산에 가장 일반적으로 사용되는 Ad E1 벡터는 바이러스 복제에 필요한 E1 영역(400-3500)이 삭제된 형태입니다. 또한, 복제에 필요하지 않은 아데노바이러스 E3 유전자도 일반적으로 이러한 벡터에서 삭제되어 유전자 삽입을 위한 추가 공간을 확보합니다. 아데노바이러스 벡터의 적용 분야 및 장점이 증가함에 따라 시장 수요도 증가하고 있습니다.

바이러스 벡터 제조 시장 지역별 점유율
북미 지역은 전 세계 바이러스 벡터 제조 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 바이러스 벡터 제조 시장을 주도하고 있으며, 예측 기간 동안에도 이러한 추세가 지속될 것으로 예상됩니다. 이 시장은 선진 의료 인프라, 활발한 연구 개발 활동, 주요 기업들의 적극적인 참여, 그리고 감염성 질환의 증가와 같은 요인들에 의해 성장하고 있습니다.
시장 참여 기업들은 협력, 신제품 출시, 승인 획득 등의 전략을 통해 사업을 확장하고 있습니다. 예를 들어, 2022년 10월, 길리어드(Gilead) 계열사인 카이트(Kite)는 미국 식품의약국(FDA)으로부터 캘리포니아에 위치한 자사의 레트로바이러스 벡터(RVV) 제조 시설의 상업 생산 승인을 받았다고 발표했습니다. 바이러스 벡터는 특정 혈액암 치료를 위한 카이트의 세포 치료제 제조에 핵심적인 역할을 합니다. 또한, 2020년 11월에는 글로벌 위탁 개발 및 제조 기업인 비발로직스(Vibalogics)가 미국 보스턴 인근에 11만 평방피트 규모의 시설을 건설하기 위해 1억 5천만 달러를 투자할 계획을 발표했습니다. 이 시설은 임상 및 상업 단계의 종양용해 바이러스와 바이러스 벡터를 생산할 것입니다.
또한, 2020년 4월 아스트라제네카와 옥스퍼드 대학교는 변형된 복제 불능 아데노바이러스 벡터인 ChAdOx1 침팬지 아데노바이러스 벡터를 이용한 바이러스 백신 개발을 위해 협력했습니다. 얀센 바이오테크(존슨앤존슨) 역시 복제 불능 인간 아데노바이러스 벡터를 이용한 바이러스 벡터 백신을 개발했으며, 2021년 2월 FDA의 승인을 받았습니다.
바이러스 벡터 제조 기업 및 경쟁 환경
바이러스 벡터 제조 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics(Charles River Laboratories), UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Inc., Spark Therapeutics 등이 있습니다. 주요 업체들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 채택하여 전 세계 바이러스 벡터 제조 시장의 성장에 기여하고 있습니다.
예를 들어,
• 2022년 6월, Avid Bioservices, Inc.는 자사의 새로운 세계적 수준의 바이러스 벡터 개발 및 우수 의약품 제조 시설(CGMP) 내에 분석 및 공정 개발(AD/PD) 스위트를 개설했습니다. 바이러스 벡터 시설의 CGMP 제조 스위트 구축은 현재 진행 중이며, 2023년 중반에 가동될 예정입니다.
Lonza
개요:
Lonza Group은 1897년에 설립되어 스위스 바젤에 본사를 둔 스위스 다국적 생명공학, 제약 및 영양 분야 제조 기업입니다. 20년 이상의 바이러스 벡터 제조 경험을 보유하고 있으며, AAV, 렌티바이러스 및 아데노바이러스 벡터를 제공합니다.

제품 포트폴리오:
AAV 생산 플라스미드: AAV 생산 플라스미드는 균형 잡힌 Rep/Cap 발현, 높은 생산성 및 역가, 그리고 다양한 AAV 혈청형 및 GOI에 최적화된 pHelper 플라스미드 및 프로모터에 대한 독자적인 노하우를 기반으로 합니다.
글로벌 바이러스 벡터 제조 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Viral Vector Manufacturing Market Overview
Viral Vector Manufacturing Market size was valued at USD 678.5 million in 2022 and is estimated to reach at a compound annual growth rate (CAGR) of 20.30% over the forecast period 2023 to 2030.The appropriate cells must first be grown and then transfected to produce viral vectors, typically using a plasmid formulation. The viral vector is then harvested from the cells and formulated for use, either as a gene therapy or for the medication of patient cells, such as in CAR-T cell therapies. For instance, the manufacture of adenoviral vectors, which are one of the common virus types used to deliver therapeutic genes, requires the conditions provided by adherent cell culture. In adherent cell culture, the cells are supported on a matrix of some type, with the two most typical options being microcarriers and multi-tray static plasticware.
Viral Vector Manufacturing Market Dynamics and Trends
The global viral vector manufacturing market is driven by technological advancements, the growing adoption of gene therapy, the demand for plasmid DNA, and gene therapy advancements.
Increasing demand for gene therapies drives market growth
The increasing disease burden, new product launches, and technological advancments drive the market in the forecast period. The capacity to make specific changes to the human genome offers a chance to address the root cause of dozens if not hundreds of diseases, but many worries that the transformative potential of these therapies will remain siloed to high-income countries. According to World Economic Forum, in October 2022, more than 300,000 babies were born each year with sickle cell disease. Nearly 75% of these births are in sub-Saharan Africa, and almost 17% are in the Arab-India region. Addressing these enormous health burdens will require improved screening and better primary care driving the viral vector manufacturing market worldwide.
In addition, the key players are applying the market strategies such as collaboration and product launches to expand their business. For instance, in May 2022, AGC Biologics announced that it is adding viral vector suspension technology and capacity for developing and manufacturing gene therapies at its commercial-grade campus in Longmont, Colo. Also, In October 2021, Merck launched a new viral vector contract development manufacturing facility for gene therapy to increase the scope of its global contract development and manufacturing organization. In October 2021, LEXEO Therapeutics partnered with FUJIFILM Diosynth Biotechnologies to facilitate the creation and manufacture of AAV-mediated gene treatments from LEXEO.
Furthermore, in January 2021, Fujifilm Corporation announced its plans to invest USD 40 million to build a new processing facility to produce viral vectors and related research. Moreover, in January 2021, Cobra Biologics (Charles River Laboratories) expanded its manufacturing facilities in Europe and the U.S. It includes expanding the HQ DNA manufacturing facility by four times and new facilities in Europe.
The challenges during viral vector manufacturing will hamper the market's growth.
However, while the manufacturing procedure for vaccine vectors is fairly templated, some challenges may occur since several other viruses with varying properties can be used. For large viral vectors, process sterility is required due to yield loss associated with sterile filtration. There are also challenges with vector aggregation and stability.
COVID-19 Impact on Viral Vector Manufacturing Market
The appearance of COVID-19 positively impacted the global viral vector manufacturing market. According to Cytiva Organization, Covid-19 viral vector vaccine manufacturing has placed additional pressure on the already stretched chimeric antigen receptor (CAR)-T cell therapy companies regarding the high need for key reagents. Viral vector manufacturing for gene therapies and viral vaccines, there has been a huge upsurge in demand for vaccine manufacturing capabilities since the pandemic's beginning.
Market players in CAR-T and vaccine production are fighting for the capabilities of viral vector producers, especially since these capacities are largely the same for adenoviral, lentiviral, and adeno-associated viral vector production. In addition, adenoviral vectors are used in the production of AstraZeneca's and Johnson & Johnson's Covid-19 vaccines, as well as for Russia's Sputnik-V and others. Lentiviral vectors are frequently used in CAR-T production. For instance, in April 2021, JNJ-78436735 or Ad26.COV2.S is an adenoviral vector-based vaccine against SARS-CoV-2 designed by Janssen pharmaceuticals of Johnson and Johnson in association with Beth Israel Deaconess Medical Center. European medicine agencies granted its authorization.
Viral Vector Manufacturing Market Segmentation Analysis
The adenoviral vectors segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The adenoviral vectors segment accounts for the largest market share. As per the CEVEC Pharmaceuticals 2021, viral vectors are increasingly important in diverse medical applications. Adenoviral (Ad) vectors have been employed over time among the different viral vectors. They have received continued attention due to the recent authorizations of Ad vector-based COVID-19 vaccines Vaxzevria (Oxford/AstraZeneca) and Janssen COVID-19 Vaccine (Johnson & Johnson). Also, in vaccine production, Ad vectors are used as one of the most suitable delivery tools in gene therapy applications and as oncolytic viruses.
Among the benefits of Ad vectors for vaccine production is their good safety profile, the capacity to produce a vital cellular and humoral immune response, the suitable transduction of both proliferating and quiescent cells, the comparative ease of vector construction, the potential of rapid virus production with high titers, and their stability. An essential safety feature of Ad vectors as delivery vehicles in gene therapy or vaccine production is their replication incompetence. This means that the virus, having introduced its essentials into the patient’s cells, cannot multiply disorderly.
To perform this, the Ad wild-type genome changed in different ways. The Ad E1 vectors most typically employed in gene therapy and vaccine production carry a deletion of the E1 region (400-3500), which is required for virus replication. Furthermore, the adenoviral E3 gene, which is not needed for replication, is usually deleted in these vectors, creating additional space for the transgene insertion. Increasing applications and advantages of adenoviral vectors lead to rising demand in the market.
Viral Vector Manufacturing Market Geographical Share
North America region holds the largest market share of the global viral vector manufacturing market
North America dominates the market for viral vector manufacturing and is anticipated to show a parallel trend over the forecast period. The market is propelled by factors such as advanced healthcare infrastructure, increasing research and development activities, active key players, and increasing infectious diseases.
The market players are adopting market strategies such as collaboration, product launches, and approval to expand their business. For instance, in October 2022, Kite, a Gilead Company, announced that the United States Food and Drug Administration (FDA) had approved the company's retroviral vector (RVV) manufacturing facility in California for commercial production. Viral vectors are key to manufacturing Kite's cell therapies to treat certain blood cancers. Also, in November 2020, a global contract development and manufacturing organization, Vibalogics, announced its plans to invest USD 150 million to build a 110,000-square-foot facility near Boston in the United States. The facility will produce clinical and commercial-stage oncolytic viruses and viral vectors.
Furthermore, in April 2020, AstraZeneca and Oxford University collaborated to develop a viral vaccine using the ChAdOx1 chimp adenovirus vector, a modified replication-deficient adenovirus vector. Janssen Biotech (Johnson & Johnson) also created a viral vector vaccination using a human adenovirus vector that is replication-incompetent, and the FDA approved it in February 2021.
Viral Vector Manufacturing Companies and Competitive Landscape
The viral vector manufacturing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics (Charles River Laboratories), UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Inc., and Spark Therapeutics, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the viral vector manufacturing market globally.
For instance,
• In June 2022, Avid Bioservices, Inc. opened the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and Current Good Manufacturing Plant (CGMP) manufacturing facility. Build-out of the viral vector facility’s CGMP manufacturing suites is ongoing, with those capabilities expected to come online in mid-calendar 2023.
Lonza
Overview:
Lonza Group is a Swiss multinational manufacturing firm for the biotechnology, pharmaceutical, and nutrition sectors, founded in 1897 and headquartered in Basel, Switzerland. The company has more than 20 years of experience in viral vector manufacturing. It provides the AAV, lentivirus, and adenoviral vectors.
Product Portfolio:
AAV Production Plasmids: AAV Production Plasmids is proprietary know-how on pHelper plasmid and promoter for balanced Rep/Cap expression, higher productivity and titers, and optimized for multiple AAV serotypes and GOIs.
The global viral vector manufacturing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising funding in pipeline research in various phases of clinical progression
4.1.1.2. Technological advancements
4.1.2. Restraints:
4.1.2.1. Short shelf-life of viral vectors
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Retroviral Vectors*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Adenoviral Vectors
7.4. Adeno-Associated Viral Vectors
7.5. Other Viral Vectors
8. By Disease
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
8.1.2. Market Attractiveness Index, By Disease
8.2. Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Genetic Disorders
8.4. Infectious Diseases
8.5. Other Diseases
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Gene Therapy*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Vaccinology
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Pharmaceutical and Biopharmaceutical Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Research Institutes
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Type Benchmarking
13. Company Profiles
13.1. Lonza*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Merck
13.3. Oxford BioMedica
13.4. CGT Catapult
13.5. Cobra Biologics (Charles River Laboratories)
13.6. UniQure
13.7. Sanofi
13.8. FUJIFILM Diosynth Biotechnologies
13.9. Cobra Biologics (Charles River Laboratories)
13.10. Thermo Fisher Scientific, Inc.
13.11. Spark Therapeutics
LIST NOT EXHAUSTIVE
14. Global Viral Vector Manufacturing Market – DataM
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

언급된 주요 기업들

Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics (Charles River Laboratories), UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Cobra Biologics (Charles River Laboratories), Thermo Fisher Scientific, Inc., Spark Therapeutics

표 목록 (Tables)

List of Tables Table 1 Global Viral Vector Manufacturing Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Viral Vector Manufacturing Market Value, By Disease, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Viral Vector Manufacturing Market Value, By Application, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Viral Vector Manufacturing Market Value, By End-User, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Viral Vector Manufacturing Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Viral Vector Manufacturing Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 7 Global Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 8 Global Viral Vector Manufacturing Market Value, By Disease, 2023, 2027 & 2031 (US$ Billion)

Table 9 Global Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 10 Global Viral Vector Manufacturing Market Value, By Application, 2023, 2027 & 2031 (US$ Billion)

Table 11 Global Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 12 Global Viral Vector Manufacturing Market Value, By End-User, 2023, 2027 & 2031 (US$ Billion)

Table 13 Global Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 14 Global Viral Vector Manufacturing Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 15 Global Viral Vector Manufacturing Market Value, By Region, 2022-2031 (US$ Billion)

Table 16 North America Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 17 North America Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 18 North America Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 19 North America Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 20 North America Viral Vector Manufacturing Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 South America Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 22 South America Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 23 South America Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 24 South America Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 25 South America Viral Vector Manufacturing Market Value, By Country, 2022-2031 (US$ Billion)

Table 26 Europe Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 27 Europe Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 28 Europe Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 29 Europe Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 30 Europe Viral Vector Manufacturing Market Value, By Country, 2022-2031 (US$ Billion)

Table 31 Asia-Pacific Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 32 Asia-Pacific Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 33 Asia-Pacific Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 34 Asia-Pacific Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 35 Asia-Pacific Viral Vector Manufacturing Market Value, By Country, 2022-2031 (US$ Billion)

Table 36 Middle East & Africa Viral Vector Manufacturing Market Value, By Type, 2022-2031 (US$ Billion)

Table 37 Middle East & Africa Viral Vector Manufacturing Market Value, By Disease, 2022-2031 (US$ Billion)

Table 38 Middle East & Africa Viral Vector Manufacturing Market Value, By Application, 2022-2031 (US$ Billion)

Table 39 Middle East & Africa Viral Vector Manufacturing Market Value, By End-User, 2022-2031 (US$ Billion)

Table 40 Sanofi SA: Overview

Table 41 Sanofi SA: Product Portfolio

Table 42 Sanofi SA: Key Developments

Table 43 Thermo Fisher Scientific Inc.: Overview

Table 44 Thermo Fisher Scientific Inc.: Product Portfolio

Table 45 Thermo Fisher Scientific Inc.: Key Developments

Table 46 Cobra Biologics Ltd: Overview

Table 47 Cobra Biologics Ltd: Product Portfolio

Table 48 Cobra Biologics Ltd: Key Developments

Table 49 Lonza Group Ltd: Overview

Table 50 Lonza Group Ltd: Product Portfolio

Table 51 Lonza Group Ltd: Key Developments

Table 52 Merck & Co.: Overview

Table 53 Merck & Co.: Product Portfolio

Table 54 Merck & Co.: Key Developments

Table 55 Oxford BioMedica: Overview

Table 56 Oxford BioMedica: Product Portfolio

Table 57 Oxford BioMedica: Key Developments

Table 58 CGT Catapult: Overview

Table 59 CGT Catapult: Product Portfolio

Table 60 CGT Catapult: Key Developments

Table 61 UniQure NV: Overview

Table 62 UniQure NV: Product Portfolio

Table 63 UniQure NV: Key Developments

Table 64 FUJIFILM Diosynth Biotechnologies: Overview

Table 65 FUJIFILM Diosynth Biotechnologies: Product Portfolio

Table 66 FUJIFILM Diosynth Biotechnologies: Key Developments

Table 67 Spark Therapeutics Inc.: Overview

Table 68 Spark Therapeutics Inc.: Product Portfolio

Table 69 Spark Therapeutics Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 4 Global Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 5 Global Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 6 Global Viral Vector Manufacturing Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Viral Vector Manufacturing Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Retroviral Vectors Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 9 Adenoviral Vectors Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 10 Adeno-Associated Viral Vectors Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 11 Others Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 12 Global Viral Vector Manufacturing Market Y-o-Y Growth, By Disease, 2022-2030 (%)

Figure 13 Cancer Disease in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 14 Genetic Disorders Disease in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 15 Infectious Diseases Disease in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 16 Others Disease in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 17 Global Viral Vector Manufacturing Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 18 Gene Therapy Application in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 19 Vaccinology Application in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 20 Global Viral Vector Manufacturing Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 21 Pharmaceutical and Biopharmaceutical Companies End-User in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 22 Research Institutes End-User in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 23 Others End-User in Global Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 24 Global Viral Vector Manufacturing Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 26 Asia-Pacific Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 27 Europe Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 28 South America Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 29 Middle East and Africa Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 30 North America Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 31 North America Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 32 North America Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 33 North America Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 34 North America Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 35 North America Viral Vector Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 36 South America Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 37 South America Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 38 South America Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 39 South America Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 40 South America Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 41 South America Viral Vector Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 42 Europe Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 43 Europe Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 44 Europe Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 45 Europe Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 46 Europe Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 47 Europe Viral Vector Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 48 Asia-Pacific Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 49 Asia-Pacific Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 50 Asia-Pacific Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 51 Asia-Pacific Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 52 Asia-Pacific Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 53 Asia-Pacific Viral Vector Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 54 Middle East & Africa Viral Vector Manufacturing Market Value, 2022-2031 (US$ Billion)

Figure 55 Middle East & Africa Viral Vector Manufacturing Market Share, By Type, 2022 & 2031 (%)

Figure 56 Middle East & Africa Viral Vector Manufacturing Market Share, By Disease, 2022 & 2031 (%)

Figure 57 Middle East & Africa Viral Vector Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 58 Middle East & Africa Viral Vector Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 59 Sanofi SA: Financials

Figure 60 Thermo Fisher Scientific Inc.: Financials

Figure 61 Cobra Biologics Ltd: Financials

Figure 62 Lonza Group Ltd: Financials

Figure 63 Merck & Co.: Financials

Figure 64 Oxford BioMedica: Financials

Figure 65 CGT Catapult: Financials

Figure 66 UniQure NV: Financials

Figure 67 FUJIFILM Diosynth Biotechnologies: Financials

Figure 68 Spark Therapeutics Inc.: Financials